EcoDrugPlus

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSNBRG00000017302
Gene Symbol: LOC102790130
3 Cross references
188 Possible Orthologues:

Camp And Camp-Inhibited Cgmp 3',5'-Cyclic Phosphodiesterase 10a-Like

Ensembl ID : ENSNBRG00000015624
Gene Symbol: LOC102777491
3 Cross references
205 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4d-Like

Ensembl ID : ENSNBRG00000007416
Gene Symbol: LOC102791271
2 Cross references
188 Possible Orthologues:

Cgmp-Specific 3',5'-Cyclic Phosphodiesterase-Like

Ensembl ID : ENSNBRG00000000777
Gene Symbol: LOC102791583
3 Cross references
221 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSNBRG00000003260
Gene Symbol: CACNG7A
2 Cross references
184 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 8a

Ensembl ID : ENSNBRG00000003244
Gene Symbol: CACNG8A
1 Cross references
167 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSNBRG00000022021
Gene Symbol: CASR
3 Cross references
202 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSNBRG00000022768
Gene Symbol: CACNA2D1
4 Cross references
226 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSNBRG00000001103
Gene Symbol: CACNA2D2
3 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSNBRG00000019856
Gene Symbol: CACNA2D3
2 Cross references
214 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSNBRG00000004111
Gene Symbol: CACNA2D4
3 Cross references
234 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Beta 3

Ensembl ID : ENSNBRG00000014539
Gene Symbol: CACNB3
1 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).